News
Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.
BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets
VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...
What happens if you stop GLP-1 weight loss injections like semaglutide and tirzepatide? Dr Bernard Tan from Bay Medical ...
More than 20 million people globally are injecting themselves with GLP-1s... Weight-loss pills will only see that explode ...
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy ...
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks.
People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...
Study Finds on MSN2d
Taking Semaglutide Could Cut Dementia Risk Nearly In Half, Case Western Study ShowsBeyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...
Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.
Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...
Signs of advanced chronic pancreatitis include weight loss, a loss of appetite, jaundice, other symptoms associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback